TY  - JOUR
T1  - Revisiting immunotherapeutic strategies for the management of atopic dermatitis
AU  - Siwe, Gael Tchokomeni
AU  - Fajemisin, Emmanuel Adebowale
AU  - Mugeri, Masala
AU  - Naran, Krupa
AU  - Barth, Stefan
Y1  - 2024///
JO  - Exploration of Asthma & Allergy
VL  - 2
IS  - 5
SP  - 373
EP  - 398
DO  - 10.37349/eaa.2024.00052
UR  - https://www.explorationpub.com/Journals/eaa/Article/100952
AB  - Atopic dermatitis (AD) represents the most common inflammatory skin disease with a highly intricated immune fingerprint. Until recently, AD management mostly relied on topical corticosteroids, calcineurin inhibitors, and systemic immunosuppressants, with a range of safety and tolerability concerns including toxicity, drug interactions, and contraindications. With the onset of biologics, safer and more targeted therapeutics have become available, displaying various degrees of success in treating AD, but not yet able to meet all the needs of AD patients. Some of the challenges encountered included variability of responses among patients, long-term safety, and limited access due to prohibitive costs. As the pathophysiology of AD has been increasingly understood within the last years, new approaches are explored, leading to an unprecedented diversification of therapeutic options to address these hurdles. This review highlights current immunotherapeutic strategies developed towards AD, whether already in the clinical pipeline or still in preclinical exploration.
ER  -